Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

NCT02475655 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Ruxolitinib

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)